

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07H 21/04, C12Q 1/68</b>		A1	(11) International Publication Number: <b>WO 97/02281</b> (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/AU96/00387		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 25 June 1996 (25.06.96)			
(30) Priority Data: PN 3916	30 June 1995 (30.06.95)	AU	
(71) Applicant (for all designated States except US): MURDOCH UNIVERSITY [AU/AU]; South Street, Murdoch, W.A. 6150 (AU).			Published <i>With international search report.</i>
(72) Inventors; and (75) Inventors/Applicants (for US only): MORGAN, Una [AU/AU]; (AU). THOMPSON, Richard, Christopher, Andrew [AU/AU]; Institute for Molecular Genetics and Animal Disease and the State Agricultural Biotechnology CentreSchool of Veterinary Science, Murdoch University South Street, Murdoch, W.A. 6150 (AU).			
(74) Agents: HARWOOD, Errol, John et al.; Wray & Associates, 239 Adelaide Terrace, Perth, W.A. 6000 (AU).			

(54) Title: NOVEL DETECTION METHODS FOR CRYPTOSPORIDIUM

(57) Abstract

The invention provides a purified and isolated *Cryptosporidium* DNA sequence comprising the nucleotide sequence: GATGGTACTGGATAGATAGTGGAAAGTCCCGTATCAGTTGAGATTCTGAAATTAAATTGGA-CATCAAGTTATAAAGCAAGCTGGTTATTAAGATTCAAATTCCCTTGTGGCTTTTGATATTGGAGGGTTAGGAA-GAAGGTT plus methods and kits for detecting and/or identifying the presence of *Cryptosporidium*.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AM</b>	Armenia	<b>GB</b>	United Kingdom	<b>MW</b>	Malawi
<b>AT</b>	Austria	<b>GE</b>	Georgia	<b>MX</b>	Mexico
<b>AU</b>	Australia	<b>GN</b>	Guinea	<b>NE</b>	Niger
<b>BB</b>	Barbados	<b>GR</b>	Greece	<b>NL</b>	Netherlands
<b>BE</b>	Belgium	<b>HU</b>	Hungary	<b>NO</b>	Norway
<b>BF</b>	Burkina Faso	<b>IE</b>	Ireland	<b>NZ</b>	New Zealand
<b>BG</b>	Bulgaria	<b>IT</b>	Italy	<b>PL</b>	Poland
<b>BJ</b>	Benin	<b>JP</b>	Japan	<b>PT</b>	Portugal
<b>BR</b>	Brazil	<b>KE</b>	Kenya	<b>RO</b>	Romania
<b>BY</b>	Belarus	<b>KG</b>	Kyrgyzstan	<b>RU</b>	Russian Federation
<b>CA</b>	Canada	<b>KP</b>	Democratic People's Republic of Korea	<b>SD</b>	Sudan
<b>CF</b>	Central African Republic	<b>KR</b>	Republic of Korea	<b>SE</b>	Sweden
<b>CG</b>	Congo	<b>KZ</b>	Kazakhstan	<b>SG</b>	Singapore
<b>CH</b>	Switzerland	<b>LI</b>	Liechtenstein	<b>SI</b>	Slovenia
<b>CI</b>	Côte d'Ivoire	<b>LK</b>	Sri Lanka	<b>SK</b>	Slovakia
<b>CM</b>	Cameroon	<b>LR</b>	Liberia	<b>SN</b>	Senegal
<b>CN</b>	China	<b>LT</b>	Lithuania	<b>SZ</b>	Swaziland
<b>CS</b>	Czechoslovakia	<b>LU</b>	Luxembourg	<b>TD</b>	Chad
<b>CZ</b>	Czech Republic	<b>LV</b>	Latvia	<b>TG</b>	Togo
<b>DE</b>	Germany	<b>MC</b>	Monaco	<b>TJ</b>	Tajikistan
<b>DK</b>	Denmark	<b>MD</b>	Republic of Moldova	<b>TT</b>	Trinidad and Tobago
<b>EE</b>	Estonia	<b>MG</b>	Madagascar	<b>UA</b>	Ukraine
<b>ES</b>	Spain	<b>ML</b>	Mali	<b>UG</b>	Uganda
<b>FI</b>	Finland	<b>MN</b>	Mongolia	<b>US</b>	United States of America
<b>FR</b>	France	<b>MR</b>	Mauritania	<b>UZ</b>	Uzbekistan
<b>GA</b>	Gabon			<b>VN</b>	Viet Nam

**Novel detection methods for *Cryptosporidium***

The present invention relates to a method for detecting microorganisms of the genus *Cryptosporidium* and more particularly *Cryptosporidium parvum*.

The protozoan parasite *Cryptosporidium parvum* is recognised as an important cause of diarrhoeal illness primarily in infants and young children, (although immunologically healthy adults are susceptible) and is associated with persistent diarrhoea and severe illness in malnourished children. It is also a serious opportunistic pathogen in immunocompromised individuals, causing severe and unremitting diarrhoea that is often intractable to therapy. Chronic cryptosporidiosis is reported in as many as 10% of persons with AIDS in the United States and there are currently no effective therapeutic strategies for treating *Cryptosporidium* infection.

Waterborne transmission of this enteric parasite is a major concern. The infective stage (oocyst) of *Cryptosporidium* is transmitted by the faecal-oral route, with infected individuals excreting *Cryptosporidium* oocysts. Animals as well as humans may serve as sources of environmental contamination and human infection. The oocyst is environmentally stable and is able to survive and penetrate routine wastewater treatment and is resistant to inactivation by drinking water disinfectants. There are several species of *Cryptosporidium* but *Cryptosporidium parvum* is believed to cause the majority of mammalian infections. *Cryptosporidium parvum* oocysts are resistant to chlorination procedures normally used for water treatment, and contamination of water supplies can cause massive outbreaks of the disease such as the 1994 outbreak of cryptosporidiosis in Milwaukee resulting in diarrhoeal illness in an estimated 403,000 people.

In the absence of effective drugs to treat this ubiquitous infection, the control and clinical management of cryptosporidiosis depends upon rapid, accurate and

- 2 -

sensitive diagnosis of the presence of the parasite, both in clinical specimens and environmental samples.

Clinical diagnosis of *Cryptosporidium* is time consuming, insensitive and generally requires the skills of highly trained operators. It has recently been

5 reported that the detection limits of conventional diagnostic techniques for *Cryptosporidium* were as low as 50,000 oocysts per gram of faeces and that mean oocyst losses ranged from 51.2% to 99.6%. Further, the most commonly used coprodiagnostic techniques may fail to detect cryptosporidiosis in many immunocompromised and immunocompetent individuals. Immunological-based

10 detection methods using immunofluorescence assays, enzyme-linked-immunosorbent and immunofluorescent-based diagnostic tests have been developed, several of which are now commercially available. Enzyme-linked immunoassays, although quick and easy to perform, generally show low sensitivity ranging from  $3 \times 10^5$  to  $1 \times 10^3$  oocysts per gram of faeces and

15 monoclonal antibodies have the ability to bind to other microorganisms, i.e., to stain nonspecifically. In addition, *Cryptosporidium* isolates have been shown to exhibit a great deal of antigenic variability and therefore diagnostic antibodies may not recognise all isolates.

Environmental detection of *Cryptosporidium* generally involves filtering large

20 volumes of water and examining it microscopically for *Cryptosporidium* oocysts by various staining or immunolabelling techniques. However, the efficiency of oocyst recovery may be as low as 1.3 to 5.5%. Recently, an alternative means of harvesting oocysts by calcium carbonate flocculation has been described with improved recovery ranging from 68% to >80%. Specialised flow cytometry and

25 cell sorting techniques have also been developed to detect oocysts in water samples with greater sensitivity than conventional fluorescence microscopy. Although these methods are significantly more sensitive and considerably faster than conventional methods, they are costly and still require the skills of highly trained technical operators.

The development of the polymerase chain reaction (PCR) has permitted specific and sensitive detection of pathogens for clinical diagnosis and environmental monitoring. Diagnostic PCR primers have been described for the detection of *Cryptosporidium*. However, these primers suffer from a lack of sensitivity and

5 are only able to detect at best approximately 200 *Cryptosporidium* oocysts reliably under optimum conditions. Further, most of the primers selected to date have only been tested on a small number of *Cryptosporidium* isolates and none of them have been tested directly on faeces. Thus, there exists a need for a sensitive detection method which is capable of identifying the presence of

10 *Cryptosporidium* in faeces and environmental samples.

Given the severity and untreatable nature of *Cryptosporidium* infection in persons with AIDS, early detection of cryptosporidial infection in HIV-infected or AIDS patients who may be shedding low numbers of oocysts becomes increasingly important. A rapid, sensitive assay requiring little or no expertise on

15 the part of the operator would be of great benefit in the early detection of asymptomatic or mild cryptosporidial infection in AIDS patients. It would improve clinical management of the disease with the option of initiating chemotherapy before the onset of symptoms, which may result in fewer cases progressing to severe, and often chronic, infections of this parasite.

20 The present invention provides nucleotide sequences which may be utilised in diagnostic assays to analyse samples for environmental contamination by *Cryptosporidium* oocysts and for the diagnosis of *Cryptosporidium* infections in patients.

Thus, the invention consists of a purified and isolated *Cryptosporidium* DNA sequence comprising the nucleotide sequence:

GATGGTACTGGATAGATAGTGGAAAGTCCCGTATCAGTCGAGATTCTGAAATTAAATTGG  
ACATCAAGTTATAAAGCAAGCTGGTTATTAAGATTCAAATTCCCTTGAAAAGTGTGG  
CTTTTTGATATTGGAGGGTTAGGAAGAAGGCCGTGGCTTATAGATTCTGAGCTT  
CTTGTGCAGTTGTGGTACAGTAGCTTATGATTCTGGTGGCTGAATCCCAATAAATAT  
30 TCAGAGCTAATTAAGCAGACTGATGAAATTATTAGTAAAGAGCCAAAGCTTGATCTTCC

- 4 -

AGGTTACAATAATTGAACGTACAGATGCTGGGAGAATAATTTATCAGTTGGTCTT  
GTCAAAATGTCTCAAATATCCTGGACTCAGCTGGAGCTCGTATCAGAGTTCGTTAAC  
TTTCCTAGTATCAACTTAACGGAAAGAGGATTCAACTAACGAAGGAGGGGACCAAGT  
TTACCATAATTCTTATTGGATCTTCCAAGGTATAAGCAGAAGAAAACATTTATTGGG  
5 ATCAGGATCCAGGTACTATTCCAGCTTGTCTGATGAAATGAAGCTCATTGGTTAAC  
GCTCAACCAACATACCATCCTTGGATAGAAGCTCATCTGGAAGTTTGAGTCTGATAG  
TACAGAATCCGGCGTGCATGAAGAAAGAACGATA

Preferably, the present invention consists of a method for detecting and/or identifying the presence of *Cryptosporidium* genomic material in a sample, said 10 method comprising the steps of: selecting at least a primer or probe derived from the above mentioned nucleotide sequence; and then using that primer or probe to detect and/or identify the presence of *Cryptosporidium* genomic material.

From the above nucleotide sequence, oligonucleotides can be prepared which hybridise with the *Cryptosporidium* genome. The oligonucleotides may be used 15 either as a primer(s) or as a probe(s) to detect the *Cryptosporidium* genome. Preferably, the primer(s) or probe(s) are specific for microorganisms of the species *Cryptosporidium parvum*.

The primer(s) or probe(s) for *Cryptosporidium* are preferably of a length which allows for the specific detection of such microorganisms. Primer(s) or probe(s) 20 which are 5 to 8 nucleotides in length should be suitable for detecting the *Cryptosporidium* genome. Preferably, sequences of 10 to 50 nucleotides may be used as primer(s) or probe(s). More particularly, sequences of about 15 to 25 nucleotides may be used in the identification protocols, and about 20 to 24 nucleotides appear optimal.

25 Primer(s) or probe(s) can be selected and prepared using routine methods, including automated oligonucleotide synthetic methods. A complement to any unique portion of the above nucleotide sequence may be used as a primer(s) or probe(s) provided that it specifically binds to the *Cryptosporidium* genome. When used as primer(s) or probe(s) complete complementarity is desirable,

- 5 -

though it may be unnecessary as the length of the fragment is increased. Among useful primer(s) or probe(s) for selecting and/or identifying *Cryptosporidium* isolates are, for example, the following sequences:

	(i)	5' GGTACTGGATAGATAGTGG 3'
5	(ii)	5' TCGCACGCCGGATTCTGTA 3'
	(iii)	5' AGTCCC GTATCAGTT CGAGA 3'
	(iv)	5' ACTGGATAGATAGTGGAAAGT 3'
	(v)	5' TTTCTTCTTCATT CGCACG 3'
	(vi)	5' GTGGAAGTCCC GTATCAGTC 3'
10	(vii)	5' ACGCCC GGATTCTGTACTAT 3'
	(viii)	5' GATAGATAGTGGAAAGTCCCG 3'
	(ix)	5' ACGCCC GGATTCTGTACTAT 3'
	(x)	5' CTGAAATTAAATTGGACATCA 3'
	(xi)	5' GTACTATCAGACTCAAAACT 3'
15	(xii)	5' GTGGTACTGGATAGATAGT 3'
	(xiii)	5' GTATCGTTCTTCATT 3'
	(xiv)	5' TGGTACTGGATAGATAGTGG 3'
	(xv)	5' TATCGTTCTTCATT 3'
	(xvi)	5' TAGATAGTGGAAAGTCCCGTA 3'
20	(xvii)	5' TCTTCATT CGCACGCCGG 3'
	(xviii)	5' ATAGTGGAAAGTCCCGTATCA 3'
	(xix)	5' TTTCTTCATT CGCACGCCCG 3'
	(xx)	5' CTGGATAGATAGTGGAGTC 3'
	(xxi)	5' CGTTTCTTCATT CGCA 3'
25	(xxii)	5' TAATTGGACATCAAGTATAA 3'
	(xxiii)	5' GTACTATCAGACTCAAAACT 3'
	(xxiv)	5' TCTGAAATTAAATTGGACATC 3'
	(xxv)	5' CTTCCAGATGAGCTTCTATC 3'
	(xxvi)	5' GGTGGTACTGGATAGATAGT 3'
30	(xxvii)	5' GGTATCGTTCTTCATT 3'
	(xxviii)	5' GAGATTCTGAAATTAAATTGG 3'

- 6 -

(xxix) 5' GTTGGCTTATAGATTCTGAGC 3'  
(xxx) 5' GGTTATTAAGATTCAAATTCC 3'  
(xxxi) 5' TCCCGTATCAGTCGAGATTCTG 3'  
(xxxii) 5' CGAACTCTGATACGAGCTCCAAGC 3'  
5 (xxxiii) 5' ATTGAGATTCTGAAATTAATTGG 3'  
(xxxiv) 5' GAATAGTACCTGGATCCTGATCCC 3'  
(xxxv) 5' GATATTGGAGGGTTAGGAAGAAGG 3'  
(xxxvi) 5' CTGTACAGTTCAAATTATTGTAACC 3'  
(xxxvii) 5' GACTGATGAAATTATTAGTAAAGAGC 3'  
10 (xxxviii) 5' CCTCCTTCGTTAGTTGAATCCTC 3'  
(xxxix) 5' TCGCACGCCCGGATTCTGTA 3'  
(xi) 5' CAGTTCAAATTATTGTAGCC 3'  
(xli) 5' GTTCGAGATTCTGAAATTAATTGG 3'  
(xlii) 5' GTCCCGTATCAGTCGAGATTCTG 3'  
15 (xliii) 5' GGAGGGTTAGGAAGAAGGCCGTG 3'  
(xlv) 5' GCTTGGGAGAATAATTATCAG 3'  
(xlv) 5' GGGATCAGGATCCAGGTACTATTC 3'  
(xlivi) 5' GTATCGTTCTTCTTCATTCGC 3'  
(xlvii) 5' GGACCAAGTTACCATAATTTC 3'  
20 (xlviii) 5' GGAGAATAATTATCAGTTGGTC 3'  
(xlix) 5' CAAGGTATAAGCAGAAGAAAAAC 3'  
(I) 5' CGCACGCCCGGATTCTGTACTATC 3'  
(ii) 5' ATGTCTCAAATATCCTGGACTCAG 3'  
(iii) 5' GTACTGGATAGATAGTGGAGTC 3'  
25 (liii) 5' CACGGCCTTCTTCCTAACCCCTCC 3'  
(liv) 5' GGAAGTCCCGTATCAGTCGAG 3'

Before the above probe(s) or primer(s) are used to detect and/or identify *Cryptosporidium* isolates in diagnostic methods such as those discussed herein, the sample to be analysed, such as a faecal sample, is preferably treated to  
30 extract the nucleic acid material contained therein. The resulting nucleic acid material from the sample may then be subjected to gel electrophoresis or other

size separation techniques; the nucleic acid material may be blotted without size separation; alternatively, the sample may be tested without being subjected to such techniques. Whether size separation is employed in the identification protocol will depend on the type of assay being used. For example, size separation may be useful in hybridization assays.

Depending on the detection method which is employed to detect and/ or identify the presence of *Cryptosporidium* isolates in a sample, the probe(s) or primer(s) may be labelled. Suitable labels and methods for labelling probes and primers are known in the art. For example, probes or primers may be labelled using

10 radioactive deoxynucleotide labels incorporated by nick translation or end labelling, biotin labels, fluorescent labels or chemiluminescent labels may also be used. Alternatively, *Cryptosporidium* specific polynucleotides may be detected on agarose or poly acrylamide gels using, for example, ethidium bromide/UV visualisation or by silver staining techniques.

15 In one detection method, *Cryptosporidium* specific polynucleotides extracted from the sample may be treated with a labelled probe under hybridisation conditions of suitable stringencies. Usually high stringency conditions are desirable to prevent false positives. The stringency of hybridisation is determined by a number of factors during hybridisation and during the washing

20 procedure, including temperature, ionic strength, length of time and concentration of reactants. A person of ordinary skill in the art would understand how these factors may be used together to modify the stringency of hybridisation.

Generally, it is expected that *Cryptosporidium* DNA will be present in samples

25 from infected individuals and particularly in environmental samples at low concentrations. This level may dictate the need for amplification of the nucleic acids before they can be detected. Such amplification techniques are known in the art.

- 8 -

A method that is particularly preferred for detecting *Cryptosporidium* DNA is based on a PCR type test wherein a set of primers which are highly specific for *Cryptosporidium* DNA are used to amplify *Cryptosporidium* DNA present in a sample. The presence of the resultant product can then be detected using, for 5 example, ethidium bromide/UV visualisation or by silver staining techniques. Alternatively, colourimetric detection of the PCR products using biotinylated primers could be employed to save time and to eliminate the need for agarose gel electrophoresis. Such an assay could also be modified to suit a 96 well microtitre format for bulk processing of samples.

10 Thus, in one embodiment the invention provides a method of detecting and/or identifying microorganisms of the genus *Cryptosporidium* comprising the steps of:

- (i) selecting at least a set of primers from the above nucleotide sequence which are specific for *Cryptosporidium* DNA;

15 (ii) mixing the primers with a sample suspected of containing *Cryptosporidium* DNA;

  - (iii) amplifying any DNA to which the primers in step (ii) anneal by the polymerase chain reaction; and
  - (iv) detecting the presence of the product of step (iii).

20 Although the above method has general application to one or more species of *Cryptosporidium*, preferably the primers which are selected in step (i) are highly specific for *Cryptosporidium parvum*.

Primer pairs which may be suitable for detecting *Cryptosporidium parvum* are preferably selected from the following sequences. In each primer set described 25 the first mentioned primer represents the forward primer and the second mentioned primer represents the reverse primer.

- (i) 5' ACTGGATAGATAGTGGAAAGT 3'  
5' TTTCTTTCTTCATT CGCACG 3'
- (ii) 5' GTGGAAGTCCCGTATCAGTC 3'

- 9 -

5' ACGCCCGGATTCTGTACTAT 3'  
(iii) 5' GATAGATAGTGGAAAGTCCCG 3'  
5' ACGCCCGGATTCTGTACTAT 3'  
(iv) 5' CTGAAATTAAATTGGACATCA 3'  
5' GTACTATCAGACTCAAAACT 3'  
(v) 5' GTGGTACTGGATAGATAGTG 3'  
5' GTATCGTTCTTCATT 3'  
(vi) 5' TGGTACTGGATAGATAGTGG 3'  
5' TATCGTTCTTCATT 3'  
(vii) 5' TAGATAGTGGAAAGTCCCGTA 3'  
5' TCTTCATT CGCACGCCCGA 3'  
(viii) 5' ATAGTGGAAAGTCCCGTATCA 3'  
5' TTTCTTCATT CGCACGCCCG 3'  
(ix) 5' CTGGATAGATAGTGGAAAGTC 3'  
5' CGTTTCTTCATT CGCA 3'  
(x) 5' TAATTGGACATCAAGTATAA 3'  
5' GTACTATCAGACTCAAAACT 3'  
(xi) 5' TCTGAAATTAAATTGGACATC 3'  
5' CTTCCAGATGAGCTTCTATC 3'  
(xii) 5' GGTGGTACTGGATAGATAGT 3'  
5' GGTATCGTTCTTCATT 3'  
(xiii) 5' GGTACTGGATAGATAGTGG 3'  
5' TCGCACGCCCGGATTCTGT 3'  
(xiv) 5' GAGATTCTGAAATTAAATTGG 3'  
5' CCTCCTTCGTTAGTTGAATCC 3'  
(xv) 5' GTTGGCTTATAGATTCTGAGC 3'  
5' CAGTTCAAATTATTGTAGCC 3'  
(xvi) 5' GAGATTCTGAAATTAAATTGG 3'  
5' CAGTTCAAATTATTGTAAACC 3'  
(xvii) 5' GTTGGCTTATAGATTCTGAGC 3'  
5' CCTCCTTCGTTAGTTGAATCC 3'

- 10 -

5	(xviii)	5' TAATTGGACATCAAGTTATAAAAGC 3' 5' GGAAGATCCAAATAAGAATTATGG 3'
10	(xix)	5' GGTTATTAAGATTCAAATTTC 3' 5' CGAACTCTGATACGAGCTCCAAGC 3'
15	(xx)	5' TCCCGTATCAGTTGAGATTCTG 3' 5' CGAACTCTGATACGAGCTCCAAGC 3'
20	(xxi)	5' GTTCGAGATTCTGAAATTAAATTGG 3' 5' CGAACTCTGATACGAGCTCCAAGC 3'
25	(xxii)	5' TAATTGGACATCAAGTTATAAAAGC 3' 5' CGAACTCTGATACGAGCTCCAAGC 3'
30	(xxiii)	5' GGTTATTAAGATTCAAATTTC 3' 5' CGAACTCTGATACGAGCTCCAAGC 3'
	(xxiv)	5' TCCCGTATCAGTTGAGATTCTG 3' 5' GAATAGTACCTGGATCCTGATCCC 3'
	(xxv)	5' TAATTGGACATCAAGTTATAAAAGC 3' 5' GAATAGTACCTGGATCCTGATCCC 3'
	(xxvi)	5' GGTTATTAAGATTCAAATTTC 3' 5' GAATAGTACCTGGATCCTGATCCC 3'
	(xxvii)	5' TCCCGTATCAGTTGAGATTCTG 3' 5' GGAAGATCCAAATAAGAATTATGG 3'
	(xxviii)	5' GTTCGAGATTCTGAAATTAAATTGG 3' 5' GGAAGATCCAAATAAGAATTATGG 3'
	(xxix)	5' GGTTATTAAGATTCAAATTTC 3' 5' GGAAGATCCAAATAAGAATTATGG 3'
	(xxx)	5' ATTGAGATTCTGAAATTAAATTGG 3' 5' GAATAGTACCTGGATCCTGATCCC 3'
	(xxxi)	5' GATATTGGAGGGTTAGGAAGAAGG 3' 5' CTGTACAGTTCAAATTATTGTAACC 3'
	(xxxii)	5' GACTGATGAAATTATTAGTAAAGAGC 3' 5' CCTCCTTCGTTAGTTGAATCCTC 3'
	(xxxiii)	5' GGTACTGGATAGATGTGGAAG 3'

- 11 -

- 5' CCAGAACATAAGCTACTGTACC 3'
- (xxxiv) 5' GTCCCGTATCAGTTGAGATTCTG 3'
- 5' CCTCCTCGTTAGTTGAATCCTC 3'
- (xxxv) 5' GGGATCAGGATCCAGGTACTATTC 3'
- 5' GTATCGTTCTTCATTCGC 3'
- (xxxvi) 5' GCTTGGGAGAATAATTATCAG 3'
- 5' CCTCCTCGTTAGTTGAATCCTC 3'
- (xxxvii) 5' GGACCAAGTTACCATATAATTTC 3'
- 5' GTATCGTTCTTCATTCGC 3'
- 10 (xxxviii) 5' GGAGAATAATTATCAGTTGGTC 3'
- 5' GTATCGTTCTTCATTCGC 3'
- (xxxix) 5' CAAGGTATAAGCAGAAGAAAAC 3'
- 5' CGCACGCCGGATTCTGTACTATC 3'
- (xli) 5' ATGTCTCAAATATCCTGGACTCAG 3'
- 15 5' CGCACGCCGGATTCTGTACTATC 3'
- (xlii) 5' GTACTGGATAGATAGTGGAAAGTC 3'
- 5' CACGGCCTTCTTCCTAACCCCTCC 3'

Particularly preferred primer pairs that may be used in a diagnostic method for detecting *Cryptosporidium parvum* are desirably selected from the following 20 primer sets. In each primer set described the first mentioned primer represents the forward primer and the second mentioned primer represents the reverse primer.

- (i) 5' GGTACTGGATAGATAGTGG 3'
- 5' TCGCACGCCGGATTCTGT 3'
- 25 (ii) 5' GAGATTCTGAAATTAAATTGG 3'
- 5' CCTCCTCGTTAGTTGAATCC 3'
- (iii) 5' GTTGGCTTATAGATTCTGAGC 3'
- 5' CAGTTCAAATTATTGTAGCC 3'
- (iv) 5' GAGATTCTGAAATTAAATTGG 3'
- 30 5' CAGTTCAAATTATTGTAAACC 3'

- 12 -

(v) 5' GTTGGCTTATAGATTCTGAGC 3'  
5' CCTCCTTCGTTAGTTGAATCC 3'

(vi) 5' TAATTGGACATCAAGTTATAAAAGC 3'  
5' GGAAGATCCAAATAAGAATTATGG 3'

5 (vii) 5' GGTTATTAAGATTCAAATTCC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'

(viii) 5' TCCCGTATCAGTTGAGATTCTG 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'

(ix) 5' GTTCGAGATTCTGAAATTAAATTGG 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'

10 (x) 5' TAATTGGACATCAAGTTATAAAAGC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'

(xi) 5' GGTTATTAAGATTCAAATTCC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'

15 (xii) 5' TCCCGTATCAGTTGAGATTCTG 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'

(xiii) 5' TAATTGGACATCAAGTTATAAAAGC 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'

(xiv) 5' GGTTATTAAGATTCAAATTCC 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'

20 (xv) 5' TCCCGTATCAGTTGAGATTCTG 3'  
5' GGAAGATCCAAATAAGAATTATGG 3'

(xvi) 5' GTTCGAGATTCTGAAATTAAATTGG 3'  
5' GGAAGATCCAAATAAGAATTATGG 3'

25 (xvii) 5' GGTTATTAAGATTCAAATTCC 3'  
5' GGAAGATCCAAATAAGAATTATGG 3'

(xviii) 5' ATTCGAGATTCTGAAATTAAATTGG 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'

(xix) 5' GATATTGGAGGGTTAGG AGAAGG 3'  
5' CTGTACAGTTCAAATTATTGTAACC 3'

30 (xx) 5' GACTGATGAAATTATTAGTAAAGAGC 3'

- 13 -

5' CCTCCTTCGTTAGTTGAATCCTC 3'  
(xxi) 5' GGTACTGGATAGATAGTGGAAAG 3'  
5' CCAGAACATCATAAGCTACTGTACC 3'  
(xxii) 5' GTCCCGTATCAGTTGAGATTCTG 3'  
5' CCTCCTTCGTTAGTTGAATCCTC 3'  
(xxiii) 5' GGGATCAGGATCCAGGTACTATT 3'  
5' GTATCGTTCTTCATTGC 3'  
(xxiv) 5' GCTTGGGAGAATAATTATCAG 3'  
5' CCTCCTTCGTTAGTTGAATCCTC 3'  
10 (xxv) 5' GGACCAAGTTACCATAATT 3'  
5' GTATCGTTCTTCATTGC 3'  
(xxvi) 5' GGAGAATAATTATCAGTTGGTC 3'  
5' GTATCGTTCTTCATTGC 3'  
(xxvii) 5' CAAGGTATAAGCAGAAGAAAAC 3'  
5' CGCACGCCGGATTCTGTACTATC 3'  
(xxviii) 5' ATGTCTCAAATATCCTGGACTCAG 3'  
5' CGCACGCCGGATTCTGTACTATC 3'  
(xxix) 5' GTACTGGATAGATAGTGGAAAGTC 3'  
5' CACGGCCTTCTTCCTAACCCCTCC 3'  
20 If for example the forward and reverse PCR primers are GGTACTGGATAGATAGTGGAA and TCGCACGCCGGATTCTGTAA respectively, a DNA fragment of approximately 668 nucleotides is produced upon amplification of *Cryptosporidium parvum* DNA. Alternatively, if the forward and reverse PCR primers are GAGATTCTGAAATTAAATTGG and CCTCCTTCGTTAGTTGAATCC  
25 respectively, a DNA fragment of approximately 426 nucleotides is produced upon amplification of *Cryptosporidium parvum* DNA.

30 The methods described herein may be used to detect the presence or absence of *Cryptosporidium* DNA. However, they provide little information about the viability or infective potential of microorganisms within a sample. Thus, the detection method(s) described *supra* may be combined with one or more

- 14 -

methods for testing *Cryptosporidium* viability. Such methods are widely known in the art. For example fluorogenic vital-dye assays (eg. using propidium iodide) or the ability of *Cryptosporidium* to grow *in vitro* or *in vivo* may be used to determine the likely infectivity or virulence of the samples tested. Care should, 5 however, be used when employing such methods. Current protocols for concentrating oocysts such as Percoll-sucrose gradients and sucrose density flotation may actually, selectively concentrate non-viable oocysts. Standard tests for viability such as fluorogenic vital-dye assays may therefore be biased towards detection of non-viable oocysts. In addition, current protocols only 10 sample a proportion of the total water body and the viability of cysts and oocysts not detected remains undetermined.

While the present invention relates to nucleotide sequences of *Cryptosporidium* and methods for detecting and/or identifying the presence of *Cryptosporidium* isolates, it will be appreciated that the sequences and method(s) may be made 15 available in the form of a kit for the detection of *Cryptosporidium* isolates. Preferably, the kit provides a means for detecting *Cryptosporidium parvum* isolates.

Thus, in one embodiment of the invention there is provided a kit of detecting and/or identifying the presence of *Cryptosporidium* microorganisms in a sample, 20 the kit comprising: at least a probe or set of primers which are specific for a region of the genome of *Cryptosporidium*, wherein the probe or primers are selected from the above mentioned nucleotide sequence.

Probes and primers can be packaged into diagnostic kits. Diagnostic kits may include the DNA probe or DNA primers which may be labelled; alternatively the 25 probe or primers may be unlabelled and the ingredients for labelling the probe or amplifying the *Cryptosporidium* DNA using the primers may be included in the kit. The kit may also contain other suitably packaged reagents and materials needed for the particular detection protocols. The kit may also contain, for example, standards, as well as instructions for using the detection kits.

- 15 -

Particular diagnostic kits may also contain the necessary reagents for conducting fluorogenic assays and/or for growing *Cryptosporidium* in cell culture.

The present invention will now be described by way of example only with reference to the following figures. It will be understood that all temperature 5 ranges and other such variables prescribed in the examples are given as indicative only, and that parameters outside these limits may also provide useful results.

**Figure 1a** represents an ethidium bromide stained 1% agarose gel showing specificity of the 021 diagnostic primers for *Cryptosporidium*.  
10 Lane 1=molecular weight marker; lane 2=*C. parvum* DNA; lane 3=*G. duodenalis* DNA; lane 4=human DNA; lane 5=faecal DNA; lane 6=*Tritrichomonas foetus* DNA; lane 7=*C. serpentis* DNA; lane 8=negative control (no DNA). Molecular weight marker was 100bp ladder (Gibco BRL); kb=kilobases.

15 **Figure 1b** shows the specificity testing of the CP1 primers. Lane 1=molecular weight marker; lane 2=*C. parvum* DNA; lane 3=*G. duodenalis* DNA; lane 4=human DNA; lane 5=faecal DNA; lane 6=*Tritrichomonas foetus* DNA; lane 7=negative control (no DNA). Molecular weight marker as in Figure 1a.

20 **Figure 2a** represents an ethidium bromide stained 1% agarose gel showing products obtained from amplification performed on 13 of the 35 *Cryptosporidium parvum* isolates examined using the 021 primers. Lane 1=molecular weight marker; lane 2=L1; lane 3=H9; lane 4=C1; lane 5=H7; lane 6=H5; lane 7=H6; lane 8=H3; lane 9=H10; lane 10=H8; lane 11=H4; lane 12=H1; lane 13=C6; lane 14=H2; lane 15=negative control. Molecular weight marker as in Figure 1a. Isolates H11-12; H15-H34; C1 and C7-9 were also tested and produced the desired 668 bp band upon amplification (data not shown).

- 16 -

**Figure 2b** illustrates parasite origin of the bands depicted in figure 2a. The gel depicted in figure 2a was blotted onto Hybond N<sup>+</sup> (Amersham) and probed with the internal oligonucleotide probes to confirm parasite origin of bands.

5      **Figure 3** represents an ethidium bromide stained 1% agarose gel showing products obtained from amplification performed on 28 of the 39 *Cryptosporidium* isolates examined using the CP1 primers. Lane 1=molecular weight marker; lane 2=H1; lane 3=H2; lane 4=H3; lane 5=H5; lane 6=H6; lane 7=H7; lane 8=H8; lane 9=H9; lane 10=H10; lane  
10     11=H11; lane 12=H12; lane 13=15; lane 14=H16; lane 15=H17; lane  
16=H18; lane 17=H19; lane 18=H20; lane 19=H21; lane 20=H22; lane  
21=H23; lane 22=H24; lane 23=H25; lane 24=H26; lane 25=C1; lane  
26=C2; lane 27=C6; lane 28=C7; lane 29=L1; lane 30=negative control.  
Isolates F1; F9; F10; F11; F20; F21; F22; F35; F36; F38 also amplified  
15     the correct 446 bp band.

20     **Figure 4a** represents an ethidium bromide stained 1% agarose gel showing the sensitivity of the 021 primers. Lane 1 = molecular weight marker; lane 2 =  $1 \times 10^5$  *C. parvum* oocysts; lane 3 =  $1 \times 10^4$  *C. parvum* oocysts; lane 4 =  $1 \times 10^3$  *C. parvum* oocysts; lane 5 = 100 *C. parvum* oocysts; lane 6 = 10 *C. parvum* oocysts; lane 7 = 1 *C. parvum* oocyst; and  
25     lane 8 = negative control. Molecular weight marker as in Figure 1a.

25     **Figure 4b** represents an ethidium bromide stained 1% agarose gel showing the sensitivity of the CP primers. Lane 1 = molecular weight marker; lane 2 =  $1 \times 10^3$  *C. parvum* oocysts; lane 3 = 100 *C. parvum* oocysts; lane 4 = 10 *C. parvum* oocysts; lane 5 = 1 *C. parvum* oocyst; lane 6 = negative control (no DNA). Molecular weight marker as in Figure 1a.

**Figure 5a** represents an ethidium bromide stained 1% agarose gel showing direct amplification of *Cryptosporidium* DNA from faeces using

- 17 -

the 021 primers. Lane 1 = molecular weight marker, lane 2 = H27; lane 3 = H28; lane 4 = H29; lane 5 = H30; lane 6 = molecular weight marker, lane 7 = H31; lane 8 = H32; lane 9 = H33; lane 10 = H34. Molecular weight marker as in Figure 1a.

5 **Figure 5b** shows amplification products from 9 faecal samples using the CP1 primers. Lane 1=molecular weight marker; lane 2 = F1; lane 3 = F9; lane 4 = F10; lane 5 = F11; lane 6 = F20; lane 7 = F21; lane 8 = F22; lane 9 = F35; lane 10 = F36; lane 11 = F38; lane 12 = negative control.

10 **Figure 6** illustrates an alignment of Human and Calf sequences of the diagnostic 02 fragment.

### Examples

#### ***Cryptosporidium* isolates**

Isolates of *Cryptosporidium* are listed in Table 1, below. *Cryptosporidium* isolates for RAPD analysis were purified from faecal DNA by PBS-ether 15 centrifugation followed by Ficoll-density centrifugation as described by Morgan, Constantine, O'Donoghue, Meloni, O'Brien & Thompson, (1995). "Molecular Characterisation of *Cryptosporidium* isolates from humans and other animals using RAPD (Random Amplified Polymorphic DNA) analysis. "American Journal of Tropical Medicine and Hygiene" 52 559-564. All faecal samples were stored 20 at 4°C without preservatives for several weeks prior to analysis.

**Table 1:** Isolates of *Cryptosporidium* used in this study

Code	Host	Species	Geographic origin	Source
H1	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H2	Human	<i>C. parvum</i>	Narrogin, Western Australia	SHL
H3	Human	<i>C. parvum</i>	Nannup Western Australia	PMH
H4	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H5	Human	<i>C. parvum</i>	Perth, Western Australia	PMH

H6	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H7	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H8	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H9	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H10	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H11	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H12	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H13	Human	<i>C. parvum</i>	Horsham, Victoria	CVL
H14	Human	<i>C. parvum</i>	Port Lincoln, South Australia	CVL
H15	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H16	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H17	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H18	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H19	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H20	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H21	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H22	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H23	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H24	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H25	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H26	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H27	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H28	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H29	Human	<i>C. parvum</i>	Bunbury, Western Australia	SHL
H30	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H31	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H32	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
H33	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
H34	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
F1	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
F9	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
F10	Human	<i>C. parvum</i>	Newman, Western Australia	SHL
F11	Human	<i>C. parvum</i>	Newman, Western Australia	SHL
F20	Human	<i>C. parvum</i>	Perth, Western Australia	SHL

- 19 -

F21	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
F22	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
F35	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
F36	Human	<i>C. parvum</i>	Perth, Western Australia	PMH
F38	Human	<i>C. parvum</i>	Perth, Western Australia	SHL
C1	Calf	<i>C. parvum</i>	Millicent, South Australia	CVL
C2	Calf	<i>C. parvum</i>	Lucindale, South Australia	CVL
C3	Calf	<i>C. parvum</i>	Meadows, South Australia	CVL
C4	Calf	<i>C. parvum</i>	Lucindale, South Australia	CVL
C5	Calf	<i>C. parvum</i>	Penola, South Australia	CVL
C6	Calf	<i>C. parvum</i>	Willunga, South Australia	CVL
C7	Calf	<i>C. parvum</i>	Penola, South Australia	CVL
C9	Calf	<i>C. parvum</i>	Maryland, U.S.A.	USDA
L1	Lamb/Deer	<i>C. parvum</i>	Edinburgh, Scotland	MAH
S1	Snake	<i>C. serpentis</i>	Tanunda, South Australia	CVL
S2	Snake	<i>C. serpentis</i>	Tanunda, South Australia	CVL

(N.B. PMH = Princess Margaret Hospital, Perth, Western Australia; SHL = State Health Laboratories, Western Australia; CVL = Central Veterinary Laboratories, South Australian Dept. of Agriculture, South Australia; MAH = Moredun Animal Health Ltd, Edinburgh, Scotland, and USDA = United States Department of Agriculture, Maryland, U.S.A; N/A = not available).

#### DNA isolation

For RAPD analysis, DNA was extracted from *Cryptosporidium* using the CTAB method described by Yap and Thompson (1987). "CTAB precipitation of cestode DNA". *Parasitology Today* 3: 220-222. *Cryptosporidium* oocysts were resuspended in 200µl of lysis buffer containing, 0.25M Sucrose; 50 mM Tris-HCl; 50 mM EDTA; 8% Triton-X-100; pH 7.5. Oocysts were subjected to three freeze-thaw cycles and then 50 µl of a 10 mg/ml proteinase K solution was added. Samples were incubated for 1 hour at 55°C and nucleic acid precipitated by the addition of 1 ml of 2% CTAB (cetyltrimethylammonium bromide). Following centrifugation, the pellet was dissolved in 250 µl of N.E. buffer (2.5 M

- 20 -

NaCl, 10 mM EDTA, pH 7.7) and diluted with 250 µl of T.E. buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). Samples were subsequently chloroform extracted once, precipitated with 100% ethanol, washed with 70% ethanol and resuspended in T.E. buffer. DNA was similarly isolated from human blood, 5 human faeces, *Giardia duodenalis*, *Tritrichomonas foetus* and *C. serpentis* for cross-hybridisation studies.

**PCR conditions and primers.**

The selection of DNA primer(s) or probe(s) by the construction and screening of genomic DNA libraries is a laborious and expensive exercise. However by using 10 the Random Amplified Polymorphic DNA (RAPD) technique described hereafter, for the development of diagnostic probes or primers, the process of selecting such nucleotide sequences is greatly simplified. In this technique, small amounts of DNA are subjected to PCR using a single oligonucleotide of random sequence as a primer. The amplification products are resolved on agarose or 15 polyacrylamide gels giving rise to a pattern that is strain specific. Many of the products generated by RAPD-PCR are derived from repetitive DNA sequences. As these sequences are frequently species-specific, RAPD-PCR is potentially a quick method for developing species-specific diagnostic PCR primers and probes

20 RAPD reactions were performed as described by Morgan, Constantine, O'Donoghue, Meloni, O'Brien & Thompson, (1995). "Molecular Characterisation of *Cryptosporidium* isolates from humans and other animals using RAPD (Random Amplified Polymorphic DNA) analysis. *"American Journal of Tropical Medicine and Hygiene"* 52 559-564. A range of primers were tested and are 25 listed below.

R-2817	5' GCTTGGTCTGCTCAATGTGG 3'
INS	5' ACAGGGGTGTGGGG 3'
PER	5' GACNGGNACNGG 3'
Y22	5' CTCTGGGTGTCGTGC 3'

SP6	5' GATTTAGGTGACACTATAG 3'
[GAA] <sup>5</sup>	5' GAAGAAGAAGAAGAA 3'
[GACA] <sup>4</sup>	5' GACAGACAGACAGACA 3'
R4	5' AGTCGAACCCTGATTCTCCGCCAGG 3'

5 **Vacuum blots, dot blots and DNA hybridisation.**

RAPD gels were vacuum blotted (BioRad) onto Hybond N<sup>+</sup> (Amersham) membranes using 20 x SSC (0.3 M Na<sub>3</sub>citrate; 3 M NaCl; pH adjusted to 7.0) as the transfer medium. Following transfer, DNA was UV cross-linked to the membranes using a GS Gene-Linker<sup>TM</sup> UV cross-linker (BioRad). Probe 10 labelling was conducted using two different non-radioactive labelling systems. The ECL (Enhanced Chemiluminescence) direct labelling kit supplied by Amersham, was used to label all double stranded DNA and the DIG (digoxigenin) oligonucleotide 3'-end labelling and detection kit supplied by Boehringer Mannheim was used to label oligonucleotides. For most 15 hybridisations, 100 ng of DNA (at a concentration of 10 ng/μl) was labelled and used in a 10 ml hybridisation volume. All hybridisations were carried out in a Hybaid<sup>TM</sup> rotisserie oven (BioRad). For dot-blots, DNA was transferred to Hybond N<sup>+</sup> membrane (Amersham), using a vacuum manifold (BioRad). DNA was bound to the membrane using the UV cross-linking procedure described 20 above.

Southern blots of RAPD profiles were hybridised to DNA isolated from human blood, *Giardia duodenalis*, human faeces and *Cryptosporidium parvum*. RAPD bands which hybridised only to *Cryptosporidium* DNA and not to the other DNA's tested were chosen for further analysis. Primers R-2817, INS, PER, Y22, SP6, 25 [GAA]<sup>5</sup> and [GACA]<sup>4</sup> all produced profiles which cross-reacted to varying degrees with human, faecal or *Giardia* DNA. The primer R4, however, produced a simple profile which cross-reacted with *Cryptosporidium* DNA only (data not shown). A band of approximately 750 bp was purified from a low-melting point gel using the syringe method described by Li. & Ownby (1993). "A rapid method 30 for extraction of DNA from agarose gels using a syringe." Biotechniques 15: 976-

978, reamplified and shown to be specific for *Cryptosporidium* by dot-blots. The band, designated 021 was then cloned and sequenced.

**Cloning of PCR products.**

Bands specific for *Cryptosporidium* were ligated directly into the pGEM T-Vector (Promega). Ligation products were transformed into *Escherichia coli* HB101 and white colonies were screened using PCR. Half of each white colony was removed with a sterile toothpick and added to a 50  $\mu$ l solution of TE buffer containing 1% Triton-X-100. The toothpick was swirled around to dislodge the cells and then discarded. These tubes were subsequently incubated at 95°C for 10 min to lyse the cells, spun for 5 min to remove cellular debris and the supernatant transferred to a clean tube.

A 5  $\mu$ l aliquot of this supernatant was used in a PCR reaction, with the M13 foreword and reverse primers. Briefly, 5  $\mu$ l of crude lysate was amplified in 67 mM Tris-HCL (pH 7.6), 16.6 mM  $(\text{NH}_4)_2\text{SO}_4$ ; 2 mM MgCl<sub>2</sub>; 200  $\mu$ M of each dNTP; 12.5 pmoles of each primer; 0.5 units of Tth Plus (Biotech International) and sterile distilled water. Reactions were performed on an OmniGene thermal cycler (Hybaid), using the following cycling conditions. One cycle of 94°C for 2 min; 55°C for 2 min and 72°C for 2 min, followed by 30 cycles of 94°C for 30 seconds; 55°C for 1 min and 72°C for 2 min with a final cycle of 94°C for 30 seconds; 55°C for 1 min and 72°C for 10 min. An aliquot (5-10 $\mu$ l) of the amplified product was then run on a 1% agarose gel and checked for size.

At least 10 white colonies for each ligation were checked for the presence of inserts using the PCR protocol described above. Inserts were cut out using Sac II and Pst 1 restriction enzymes (Pharmacia), electrophoresed on a 1% low-melting point agarose gel and the insert purified from the gel using the syringe method. At this point, inserts were again checked for specificity by dot blots and *Cryptosporidium*-specific inserts were chosen for sequencing.

Sequencing and synthesis of primers.

Sequencing was carried out using the Taq DyeDeoxy™ Terminator Cycle Sequencing Kit supplied by Applied Biosystems. Sequences were aligned using the Seqed and DNA strider programs and compared with Genebank and EMBL databases for sequence homology. A number of primer sequences were 5 designed from the 021 sequence using the computer program Amplify™ and oligonucleotides were synthesised by DNA Express.

Primers

The 021 forward and 021 reverse primers which produced a 668 bp fragment 10 upon amplification of *Cryptosporidium parvum* DNA are listed below. An oligonucleotide internal to the sequence amplified by the 021 primers was also synthesised for use as a probe to confirm parasite origin of the amplified product. A second set of primers, designated CP1 forward and reverse and an internal oligonucleotide designated CPI were also designed from the 021 15 sequence. These primers produced an approximately 426 bp fragment upon amplification of *Cryptosporidium* DNA.

	021 F	5' GGTACTGGATAGATAGTGG 3'
	021 R	5' TCGCACGCCGGATTCTGTA 3'
	Oligo	5' AGTCCCGTATCAGTCGAGA 3'
20	CP1 F	5' GAGATTCTGAAATTAAATTGG 3'
	CP1 R	5' CCTCCTTCGTTAGTTGAATCC 3'
	CPI	5' GTTGGCTTATAGATTCTGAGC 3'

The sequence of the diagnostic fragment is shown below with the positions at 25 which the primers bind underlined. The CP1 forward and reverse primers are shown binding inside the sequence specified by the 021 primers and produce a 426 bp product upon amplification.

GATGGTACTGGATAGATAGTGGAGTCCCGTATCAGTCGAGATTCTGAAATTAAATTGG  
ACATCAAGTTATAAAGCAAGCTGGTTATTAAGATTCAAATTCCCTTGAAAAGTGTGG  
CTTTTTGATATTGGAGGGTTAGGAAGAAGGCCGTGGCTTATAGATTCTGAGCTT

- 24 -

CTTGTGCAGTTGGTACAGTAGCTTATGATTCTGGTGGCTGAATCCCAATAAATAT  
TCAGAGCTAATTAAGCAGACTGATGAAATTATTAGTAAAGAGCCAAAGCTGATCTCC  
AGGTTACAATAATTGAACGTACAGATGCTGGAGAATAATTATCAGTTGGCTTT  
GTCAAAATGTCTCAAATATCCTGGACTCAGCTGGAGCTCGTATCAGAGTCGTTAAC  
5 TTTCTAGTATCAACTTAACTGGAAAGAGGATTCAACTAACGAAGGGAGGGACCAAGT  
TTACCATAATTCTTATTGGATCTTCCAAGGTATAAGCAGAAGAAAACATTATTGGG  
ATCAGGATCCAGGTACTATTCCAGCTTGTCTGATGAAATGAAGCTCATTGGTTAAC  
GCTCAACCAACATACCATCCTTGGATAGAAGCTCATCTGGAAGTTTGAGTCTGATAG  
**TACAGAATCCGGCGTGC**GAATGAAGAAAGAAACGATA

10 **Diagnostic PCR conditions.**

PCR conditions for the 021 diagnostic PCR primers consisted of 67 mM Tris-HCL (pH 7.6), 16.6 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>; 1.5 mM MgCl<sub>2</sub>; 200 µM of each dNTP; 6.5 pmoles of each primer; 0.25 units of Tth Plus (Biotech International) and sterile distilled water. Reactions were performed on an OmniGene thermal cycler  
15 (Hybaid), using the following cycling conditions. One cycle of 94°C for 2 min; 58°C for 2 min and 72°C for 2 min, followed by 40 cycles of 94°C for 30 seconds; 58°C for 1 min and 72°C for 2 min with a final cycle of 94°C for 30 seconds; 58°C for 1 min and 72°C for 10 min. PCR conditions for the CP1 primers were essentially the same except that 2 mM MgCl<sub>2</sub> and an annealing temperature of  
20 59°C was used.

**Diagnostic test.**

For sensitivity testing, crude oocyst preparations were resuspended in 10 µl of T.E. Decreasing concentrations of oocyst suspensions were prepared by serial dilutions. For direct PCR analysis of faecal samples, 0.5g of faeces was mixed  
25 with 4 ml PBS and this slurry was then diluted 1 in 20 in T.E. Samples were then freeze-thawed 3 times, boiled for 5 min, spun for 1 min to remove debris and then 5-10 µl of the supernatant was added directly to the PCR reaction.

The above oligonucleotide sequences are unique in that a comparison of the sequence information obtained from the 021 clone with Genebank and EMBL

- 25 -

databases produced no homology of any significance. The specificity of the primers designed from the 021 clone was tested by performing PCR reactions on DNA extracted from *Giardia duodenalis*, human blood, human faeces, *Tritrichomonas foetus*, and *C. serpentis*. With both sets of primers, DNA of the 5 correct size was amplified from *Cryptosporidium parvum* DNA only. No amplification was seen with any of the other DNA's tested (see Figure 1a and b).

The primers were also tested on *Cryptosporidium* of both human and bovine origin and the PCR products confirmed by hybridisation to the internal oligonucleotide. These diagnostic primers were then used to amplify over 40 10 different isolates of *Cryptosporidium parvum* of both human and bovine origin (listed in Table 1), to determine if the primers would recognise some or all isolates. All isolates tested produced the correct sized upon amplification (see Figures 2a; 2b and 3).

The gel depicted in figure 2a was then blotted onto Hybond N<sup>+</sup> (Amersham) and 15 probed with the internal oligonucleotide probes to confirm parasite origin of bands (Figure 2b).

The amplification products of the CPF primers were also probed with an internal oligonucleotide to confirm parasite origin of the bands. In all cases the 446 bp 20 amplification product hybridised strongly with the internal oligo indicating that the reaction was specific for *Cryptosporidium* (data not shown).

The detection limits of the primers were found to be as high as one oocyst (see Figure 4a) with both the 021 and the CP1 primers (see Figure 4b) when amplifying from crude preparations of oocysts.

The primers were also used to reproducibly amplify *Cryptosporidium* directly 25 from boiled faeces (see figure 5a). Most of the eight faecal samples tested contained relatively low numbers of oocysts (ranging from  $1 \times 10^3$  to  $5 \times 10^5$  oocysts per gram of faeces, with one sample, H29, containing  $1.5 \times 10^6$  oocysts per g of faeces). One sample, H27, unlike the other samples, was a solid stool

and it was necessary to perform a crude PBS-ether extraction of that sample in order to obtain a reproducible amplification product (see figure 5a).

Figure 5b shows amplification products from 9 faecal samples using the CP1 primers. Lane 1=molecular weight marker; lane 2 = F1; lane 3 = F9; lane 4 = 5 F10; lane 5 = F11; lane 6 = F20; lane 7 = F21; lane 8 = F22; lane 9 = F35; lane 10 = F36; lane 11 = F38; lane 12 = negative control.

The sequences of two human and two calf isolates of *Cryptosporidium parvum* were compared along the length of the diagnostic fragment to determine the extent of sequence conservation between isolates (see Figure 6). Direct PCR 10 sequencing was carried out using the Taq DyeDeoxy™ Terminator Cycle Sequencing Kit supplied by Applied Biosystems. Sequences were aligned using the CLUSTAL V multiple sequence alignment program. The alignment shows the sequence to be conserved between isolates but with a number of sequence differences between the human and calf isolates. These findings are in keeping 15 with RAPD analysis on these isolates described by Morgan, Constantine, O'Donoghue, Meloni, O'Brien & Thompson, (1995). "Molecular Characterisation of *Cryptosporidium* isolates from humans and other animals using RAPD (Random Amplified Polymorphic DNA) analysis. "American Journal of Tropical Medicine and Hygiene" 52 559-564, which reported genetic differences between 20 human and calf isolates. The observed differences between the human and calf isolates is not sufficient to interfere with primer binding and both human and calf isolates are amplified using both the 021 and the CP1 primers (primer sequences are underlined). Given the differences between the human and calf isolates however, it would be possible to construct primers which could 25 differentiate between human and animal isolates (ie a set of primers which would amplify human isolates only and a second set which would amplify calf /animal isolates only). Primers which are specific for animal or human isolates would be very useful in transmission studies and also for environmental analysis in determining the likely source of contamination of water supplies (ie human or 30 animal).

The above mentioned sequence was analysed to determine whether or not the sequence was from a coding or non-coding section of DNA. A number of computer programs were used including CODON PREFERENCE which is a frame-specific gene finder that tries to recognise protein coding sequences by virtue of the similarity of their codon usage to a codon frequency table or by the bias of their composition (usually GC) in the third position of each codon. Analysis of the sequence using these programs however, suggests that the 021 fragment is unlikely to contain coding regions.

RAPD analysis was used to develop diagnostic primers for *Cryptosporidium parvum* which have been shown to be both specific and also sensitive. Both the 021 and the CP1 primers appear to be very specific for *Cryptosporidium*, can detect as little as one oocyst and can amplify *Cryptosporidium* directly from boiled faeces. Over 47 different isolates of *Cryptosporidium parvum* of both human and bovine origin from diverse geographic locations were screened using these primers and all amplified the correct sized band, indicating that the sequence defined by the primers is conserved amongst isolates.

The specificity testing of the RAPD primers did not include *Cryptosporidium baileyi*, *Cryptosporidium meleagridis* or *Cryptosporidium muris* DNA, as a source of this material was not readily available. Although *Cryptosporidium muris* has been reported in cattle in the United States, and oocysts resembling *Cryptosporidium baileyi* were recovered from an immunocompromised human patient, these species of *Cryptosporidium* are not commonly reported in livestock and particularly not from humans. Further optimisation of the assay is required to enable the amplification of all *Cryptosporidium* isolates directly from faeces without any prior purification.

The RAPD primers described herein could be used both in the diagnosis of *Cryptosporidium* from faecal samples and also in environmental monitoring. The level of skill required by microscopic identification of *Cryptosporidium* oocysts, the low sensitivity of current diagnostic methods and varying expertise among laboratories and technicians can result in many cases of mild cryptosporidial

infection remaining undiagnosed. A simple PCR detection system employing primers of the present invention should greatly improve the detection and diagnosis of *Cryptosporidium*.

Outbreaks of cryptosporidiosis in child day care centres are frequently reported

5 (Alpert *et al.* 1986; Crawford *et al.* 1988; Diers & McCallister 1989; Ferson & Young 1992; Hanna & Brooks 1995), and family members are often affected during such outbreaks. A proportion of each group is asymptomatic and can act as carriers of infection to relatives and the community. Therefore, the public health problem of transmission to the community from these centres is a

10 significant one and needs further evaluation and control. Investigations undertaken during outbreaks of diarrhoea however, have frequently used limited diagnostic testing that have tended to incriminate agents that are easily identifiable in standard microbiological laboratories (Thompson 1994). Sensitive molecular-based tools such as the PCR primers described here will allow more

15 accurate molecular-epidemiological studies to be carried out to determine not only the true prevalence of *Cryptosporidium* in the community, but also the risk factors associated with infection.

A recent survey in the United States conducted by Clancy *et al.* (1994) "Commercial labs: how accurate are they?" Journal of the American Water Works

20 Association. 86: 89-97, revealed that commercial laboratories showed a lack of proficiency in testing water samples for *Giardia* and *Cryptosporidium*. With the implementation in 1995 of the Information Collection Rule (ICR) in the United States which makes testing for *Giardia* and *Cryptosporidium* in water systems serving more than 10,000 people mandatory, the development of accurate and

25 sensitive testing for *Cryptosporidium* is of great importance.

As a result of this study, highly sensitive and specific diagnostic PCR primers have been developed for *Cryptosporidium*.

References

ALPERT, G.L.M., BELL, C.E., KIRKPATRICK, L.D., BUDNICK, J.M., CAMPOS, H.M., FRIEDMAN, H.M. AND PLOTKIN, S.A. (1986) Outbreak of cryptosporidiosis in a day-care centre. *Pediatrics*. 77, 152-156.

5 CRAWFORD, F.G., VERMUND S.H., MA, J.Y. AND DECKELBAUM, R.J. (1988). Asymptomatic cryptosporidiosis in a New York City day care centre. *Paediatric Infectious Disease Journal*. 7, 806.

DIERS, J. & McCALLISTER G.L. (1989). Occurrence of *Cryptosporidium* in home daycare centres in West-Central Colorado. *Journal of Parasitology*. 75, 10 637-638.

FERSON, M.J. & YOUNG, L.C. (1992). *Cryptosporidium* and coxsackievirus B5 causing epidemic diarrhoea in a child-care centre. *Medical Journal of Australia*. 156, 813.

HANNA J. & BROOKS, D. (1995). Cryptosporidiosis in a child day-care centre. 15 *Communicable Disease Intelligence*. 19, 6-7.

THOMPSON, S.C. (1994). Infectious diarrhoea in children - controlling transmission in the child care setting. *Journal of Paediatric Child Health*. 30, 210-219.

- 30 -

**SEQUENCE INFORMATION****SEQ. ID. NO. 1:**

	GATGGTACTG	GATAGATAGT	GGAAGTCCCG	TATCAGTTCG	40
	AGATTCTGAA	ATTAATTGGA	CATCAAGTTA	TAAAGCAAGC	80
5	TGGTTATTAA	GATTCAAATT	TCCCTTGAA	AAGTGTGGCT	120
	TTTTTGATAT	TGGAGGGTTA	GGAAGAAGGC	CGTGTGGCT	160
	TATAGATTCT	GAGCTTCCTT	GTGCAGTTG	TGGTACAGTA	200
	GCTTATGATT	CTGGTGGGCT	GAATCCAAT	AAATATTCAAG	240
	AGCTAATTAA	GCAGACTGAT	GAAATTATTA	GTAAAGAGCC	280
10	AAAGCTTGAT	CTTCCAGGTT	ACAATAATT	GAACGTACA	320
	GATGCTTGGG	AGAATAATT	ATCAGTTGGT	CTTGTCAAA	360
	ATGTCTCAAA	TATCCTGGAC	TCAGCTTGGA	GCTCGTATCA	400
	GAGTCGTTA	AACTTCCTA	GTATCAACTT	TAACGGAAA	440
	GAGGATTCAA	CTAACGAAGG	AGGGGACCAA	TTTACCATATA	480
15	ATTCTTATTT	GGATCTTCCA	AGGTATAAGC	AGAAGAAAAC	520
	ATTTTATTGG	GATCAGGATC	CAGGTACTAT	TCCAGCTTG	560
	TCTGATGAAA	TGAAGCTCAT	TGGTTTAAGC	GCTCAACCAA	600
	CATACCATCC	TTTGGATAGA	AGCTCATCTG	GAAGTTTGA	640
	GTCTGATAGT	ACAGAATCCG	GGCGTGCAGA	TGAAGAAAGA	680
20	AACGATAAC				

THE CLAIMS defining the invention are:

1. A purified and isolated *Cryptosporidium* DNA sequence comprising the nucleotide sequence:

5                    GATGGTACTGGATAGATAGTGGAAAGTCCCGTATCAGTCGAGATTCTGAAAT  
TAATTGGACATCAAGTTATAAAGCAAGCTGGTTATTAAGATTCAAATTCCC  
TTTGAAAAGTGTGGCTTTTGATATTGGAGGGTTAGGAAGAAGGCCGTGTT  
GGCTTATAGATTCTGAGCTTCTTGTGCAGTTGTGGTACAGTAGCTTATGA  
10                TTCTGGTGGGCTGAATCCAATAAAATTCAAGAGCTAATTAAGCAGACTGAT  
GAAATTATTAGTAAAGAGCCAAAGCTTGATCTTCCAGGTTACAATAATTGA  
ACTGTACAGATGCTTGGGAGAATAATTATCAGTTGGTCTTGTCAAAATGT  
15                CTCAAATATCCTGGACTCAGCTTGGAGCTCGTATCAGAGTTCGTTAAACTTT  
CCTAGTATCAACTTTAAGTGGAAAGAGGATTCAACTAACGAAGGGAGGGACC  
AAGTTTACCATATTCTATTGGATCTTCCAAGGTATAAGCAGAAGAAAAC  
ATTTTATTGGGATCAGGATCCAGGTACTATTCCAGCTTGTCTGATGAAATG  
AAGCTCATTGGTTAACCGCTAACCAACATACCATCCTTGGATAGAAGCT  
20                CATCTGGAAGTTTGAGTCTGATAGTACAGAATCCGGCGTGCAGAATGAAGA  
AAGAAACGATAC

2. A method for detecting and/or identifying the presence of *Cryptosporidium* genomic material in a sample, said method comprising the steps of:

- 20                (i) selecting at least a primer(s) or probe from nucleotide sequence according to claim 1; and  
(ii) using the primer(s) or probe to detect and/or identify the presence of *Cryptosporidium* genomic material in the sample.
3. A method according to claim 2 wherein *Cryptosporidium* genomic material in the sample is detected by a hybridisation assay.
- 25                4. A method according to claim 2 wherein the probe or primer(s) is at least 5 nucleotides in length.
5. A method according to claim 2 wherein the probe or primer(s) is about 10 to 50 nucleotides in length.

- 32 -

6. A method according to claim 2 wherein the probe or primer(s) is about 20 to 24 nucleotides in length.
7. A method according to claim 3 wherein the probe or primer(s) is selected from one of the following sequences:
  - 5 GGTACTGGATAGATAGTGG; TCGCACGCCGGATTCTGTA;  
AGTCCCGTATCAGTCGAGA; ACTGGATAGATAGTGGAGT;  
TTTCTTCTTCATTCGCACG; GTGGAAGTCCCGTATCAGTC;  
ACGCCCGGATTCTGTACTAT; GATAGATAGTGGAGTCCCG;  
ACGCCCGGATTCTGTACTAT; CTGAAATTAATTGGACATCA;
  - 10 GTACTATCAGACTCAAAACT; GTGGTACTGGATAGATAGT;  
GTATCGTTCTTCATT; TGGTACTGGATAGATAGTGG;  
TATCGTTCTTCATT; TAGATAGTGGAGTCCCGTA;  
TCTTCATTCGCACGCCGG; ATAGTGGAGTCCCGTATCA;  
TTTCTTCATTCGCACGCCCG; CTGGATAGATAGTGGAGTC;
  - 15 CGTTTCTTCATT; TAATTGGACATCAAGTATAA;  
GTACTATCAGACTCAAAACT; TCTGAAATTAATTGGACATC;  
CTTCCAGATGAGCTTCTATC; GGTGGTACTGGATAGATAGT;  
GGTATCGTTCTTCATT; GAGATTCTGAAATTAATTGG;  
GTTGGCTTATAGATTCTGAGC; GGTTATTAAGATTCAAATTCC;
  - 20 TCCCGTATCAGTCGAGATTCTG; CGAACTCTGATACGAGCTCCAAGC;  
ATTCGAGATTCTGAAATTAATTGG; GAATAGTACCTGGATCCTGATCCC;  
GATATTGGAGGGTTAGGAAGAAGG; CTGTACAGTTCAAATTATTGTAACC;  
GACTGATGAAATTATTAGTAAAGAGC; CCTCCTCGTTAGTTGAATCCTC;  
TCGCACGCCGGATTCTGTA; CAGTTCAAATTATTGTAGCC;
  - 25 GTTCGAGATTCTGAAATTAATTGG; GTCCCGTATCAGTCGAGATTCTG;  
GGAGGGTTAGGAAGAAGGCCGTG; GCTTGGGAGAATAATTATCAG;  
GGGATCAGGATCCAGGTACTATTC; GTATCGTTCTTCATTCGC;  
GGACCAAGTTTACCATATT; GGAGAATAATTATCAGTTGGTC;  
CAAGGTATAAGCAGAAGAAAAC; CGCACGCCGGATTCTGTACTATC;
  - 30 ATGTCTCAAATATCCTGGACTCAG; GTACTGGATAGATAGTGGAGTC;  
CACGGCCTTCTCCTAACCCCTCC; or GGAAGTCCCGTATCAGTCGAG.

- 33 -

8. A method for detecting and/or identifying microorganisms of the genus *Cryptosporidium*, comprising the steps of:

(i) selecting at least a set of primers from the nucleotide sequence defined in claim 1 which are specific for *Cryptosporidium* DNA;

5 (ii) mixing the primers with a sample suspected of containing *Cryptosporidium* DNA;

(iii) amplifying the product(s) of step (ii) by the polymerase chain reaction; and

(iv) detecting the presence of the product of step (iii).

10 9. A method according to claim 7 where in the primers are selected from the following primer pairs:

(i) 5' ACTGGATAGATAGTGGAAAGT 3'  
5' TTTCTTCTTCATT CGCACG 3'

15 (ii) 5' GTGGAAGTCCC GTATCAGTC 3'  
5' ACGCCCGGATTCTGTACTAT 3'

(iii) 5' GATAGATAGTGGAAAGTCCC 3'  
5' ACGCCCGGATTCTGTACTAT 3'

(iv) 5' CTGAAATTAAATTGGACATCA 3'  
5' GTACTATCAGACTCAAAACT 3'

20 (v) 5' GTGGTACTGGATAGATAGTG 3'  
5' GTATCGTTCTTTCTTCATT 3'

(vi) 5' TGGTACTGGATAGATAGTG 3'  
5' TATCGTTCTTTCTTCATT 3'

25 (vii) 5' TAGATAGTGGAAAGTCCC GTA 3'  
5' TCTTCATT CGCACGCCCGA 3'

(viii) 5' ATAGTGGAAAGTCCC GTATCA 3'  
5' TTTCTTCATT CGCACGCCCG 3'

(ix) 5' CTGGATAGATAGTGGAAAGTC 3'  
5' CGTTTCTTTCTTCATT CGCA 3'

30 (x) 5' TAATTGGACATCAAGTATAA 3'  
5' GTACTATCAGACTCAAAACT 3'

- 34 -

- (xi) 5' TCTGAAATTAATTGGACATC 3'  
5' CTTCCAGATGAGCTTCTATC 3'
- (xii) 5' GGTGGTACTGGATAGATAGT 3'  
5' GGTATCGTTCTTCTTCAT 3'
- 5 (xiii) 5' GGTACTGGATAGATAGTGG 3'  
5' TCGCACGCCCGGATTCTGTA 3'
- (xiv) 5' GAGATTCTGAAATTAATTGG 3'  
5' CCTCCTTCGTTAGTTGAATCC 3'
- (xv) 5' GTTGGCTTATAGATTCTGAGC 3'  
5' CAGTTCAAATTATTGTAGCC 3'
- 10 (xvi) 5' GAGATTCTGAAATTAATTGG 3'  
5' CAGTTCAAATTATTGTAACC 3'
- (xvii) 5' GTTGGCTTATAGATTCTGAGC 3'  
5' CCTCCTTCGTTAGTTGAATCC 3'
- 15 (xviii) 5' TAATTGGACATCAAGTTATAAAGC 3'  
5' GGAAGATCCAAATAAGAATTATGG 3'
- (xix) 5' GGTTATTAAGATTCAAATTCC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'
- (xx) 5' TCCCGTATCAGTCGAGATTCTG 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'
- 20 (xxi) 5' GTTCGAGATTCTGAAATTAATTGG 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'
- (xxii) 5' TAATTGGACATCAAGTTATAAAGC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'
- 25 (xxiii) 5' GGTTATTAAGATTCAAATTCC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'
- (xxiv) 5' TCCCGTATCAGTCGAGATTCTG 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'
- (xxv) 5' TAATTGGACATCAAGTTATAAAGC 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'
- 30 (xxvi) 5' GGTTATTAAGATTCAAATTCC 3'

- 35 -

- 5' GAATAGTACCTGGATCCTGATCCC 3'
- (xxvii) 5' TCCCGTATCAGTCGAGATTCTG 3'
- 5' GGAAGATCCAAATAAGAATTATGG 3'
- (xxviii) 5' GTTCGAGATTCTGAAATTAATTGG 3'
- 5' GGAAGATCCAAATAAGAATTATGG 3'
- (xxix) 5' GGTTATTAAGATTCAAATTTC 3'
- 5' GGAAGATCCAAATAAGAATTATGG 3'
- (xxx) 5' ATTGAGATTCTGAAATTAATTGG 3'
- 5' GAATAGTACCTGGATCCTGATCCC 3'
- 10 (xxxi) 5' GATATTGGAGGGTTAGGAAGAAGG 3'
- 5' CTGTACAGTTCAAATTATTGTAACC 3'
- (xxxii) 5' GACTGATGAAATTATTAGTAAAGAGC 3'
- 5' CCTCCTTCGTTAGTTGAATCCTC 3'
- (xxxiii) 5' GGTACTGGATAGATAGTGGAG 3'
- 15 5' CCAGAACATCATAAGCTACTGTACC 3'
- (xxxiv) 5' GTCCCGTATCAGTCGAGATTCTG 3'
- 5' CCTCCTTCGTTAGTTGAATCCTC 3'
- (xxxv) 5' GGGATCAGGATCCAGGTACTATTC 3'
- 5' GTATCGTTCTTCATTCGC 3'
- 20 (xxxvi) 5' GCTTGGGAGAATAATTATCAG 3'
- 5' CCTCCTTCGTTAGTTGAATCCTC 3'
- (xxxvii) 5' GGACCAAGTTACCATAATTTC 3'
- 5' GTATCGTTCTTCATTCGC 3'
- (xxxviii) 5' GGAGAATAATTATCAGTTGGTC 3'
- 25 5' GTATCGTTCTTCATTCGC 3'
- (xxxix) 5' CAAGGTATAAGCAGAAGAAAAC 3'
- 5' CGCACGCCGGATTCTGTACTATC 3'
- (xli) 5' ATGTCTCAAATATCCTGGACTCAG 3'
- 5' CGCACGCCGGATTCTGTACTATC 3'
- 30 (xlii) 5' GTACTGGATAGATAGTGGAGTC 3'
- 5' CACGGCCTTCTTCCTAACCCCTCC 3'

- 36 -

10. A method according to claim 7 where in the primers are selected from the following primer pairs:

5 (i) 5' GGTACTGGATAGATAGTGGA 3'  
(ii) 5' TCGCACGCCGGATTCTGTA 3'  
10 (iii) 5' GAGATTCTGAAATTAAATTGG 3'  
5' CCTCCTTCGTTAGTTGAATCC 3'  
(iv) 5' GTTGGCTTATAGATTCTGAGC 3'  
5' CAGTTCAAATTATTGTAGCC 3'  
15 (v) 5' GAGATTCTGAAATTAAATTGG 3'  
5' CAGTTCAAATTATTGTAGCC 3'  
(vi) 5' GTTGGCTTATAGATTCTGAGC 3'  
5' CCTCCTTCGTTAGTTGAATCC 3'  
(vii) 5' TAATTGGACATCAAGTTATAAAGC 3'  
5' GGAAGATCCAAATAAGAATTATGG 3'  
20 (viii) 5' GGTTATTAAGATTCAAATTTC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'  
(ix) 5' TCCCGTATCAGTTCGAGATTCTG 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'  
(x) 5' TAATTGGACATCAAGTTATAAAGC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'  
25 (xi) 5' GGTTATTAAGATTCAAATTTC 3'  
5' CGAACTCTGATACGAGCTCCAAGC 3'  
(xii) 5' TCCCGTATCAGTTCGAGATTCTG 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'  
(xiii) 5' TAATTGGACATCAAGTTATAAAGC 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'  
30 (xiv) 5' GGTTATTAAGATTCAAATTTC 3'  
5' GAATAGTACCTGGATCCTGATCCC 3'  
(xv) 5' TCCCGTATCAGTTCGAGATTCTG 3'


- 37 -

- 5' GGAAGATCCAAATAAGAATTATGG 3'
- (xvi) 5' GTTCGAGATTCTGAAATTAATTGG 3'
- 5' GGAAGATCCAAATAAGAATTATGG 3'
- (xvii) 5' GGTTATTAAGATTCAAATTTCC 3'
- 5' GGAAGATCCAAATAAGAATTATGG 3'
- (xviii) 5' ATTCGAGATTCTGAAATTAATTGG 3'
- 5' GAATAGTACCTGGATCCTGATCCC 3'
- (xix) 5' GATATTGGAGGGTTAGGAAGAAGG 3'
- 5' CTGTACAGTTCAAATTATTGTAACC 3'
- 10 (xx) 5' GACTGATGAAATTATTAGTAAAGAGC 3'
- 5' CCTCCTTCGTTAGTTGAATCCTC 3'
- (xxi) 5' GGTACTGGATAGATAGTGGAAAG 3'
- 5' CCAGAACATCATAAGCTACTGTACC 3'
- (xxii) 5' GTCCCGTATCAGTCGAGATTCTG 3'
- 5' CCTCCTTCGTTAGTTGAATCCTC 3'
- (xxiii) 5' GGGATCAGGATCCAGGTACTATTTC 3'
- 5' GTATCGTTCTTCATTGCGC 3'
- (xxiv) 5' GCTTGGGAGAATAATTATCAG 3'
- 5' CCTCCTTCGTTAGTTGAATCCTC 3'
- 20 (xxv) 5' GGACCAAGTTACCATAATTTC 3'
- 5' GTATCGTTCTTCATTGCGC 3'
- (xxvi) 5' GGAGAACATAATTATCAGTTGGTC 3'
- 5' GTATCGTTCTTCATTGCGC 3'
- (xxvii) 5' CAAGGTATAAGCAGAACAGAAAAC 3'
- 5' CGCACGCCGGATTCTGTACTATC 3'
- 25 (xxviii) 5' ATGTCTCAAATATCCTGGACTCAG 3'
- 5' CGCACGCCGGATTCTGTACTATC 3'
- (xxix) 5' GTACTGGATAGATAGTGGAAAGTC 3'
- 5' CACGGCCTTCTTCCTAACCCCTCC 3'


- 38 -

11. A method according to claim 7 wherein the primer pair is  
GGTACTGGATAGATAGTGGA (Forward primer) and  
TCGCACGCCGGATTCTGTA (Reverse primer).
12. A method according to claim 7 wherein the primer pair is  
5 GAGATTCTGAAATTAATTGG (Forward primer) and  
CCTCCTTCGTTAGTTGAATCC (Reverse primer).
13. A method according to claims 2 or 8 wherein the method includes a further step of testing for the viability and or the infectivity of *Cryptosporidium* organisms in the sample.
- 10 14. A kit for the detection of *Cryptosporidium* isolates: the kit comprising at least a probe or primer(s) selected from the nucleotide sequence defined in claim 1, which is capable of detecting *Cryptosporidium* isolates.
15. A kit according to claim 14 wherein the kit contains a primer pair selected from the primers defined in any one of claims 9 to 12.


1 / 8




**Figure 1a**




**Figure 1b**




**Figure 2a**




**Figure 2b**




**Figure 3**




**Figure 4a**



**Figure 4b**



**Figure 5a**



**Figure 5b**

6 / 8  
**Figure 6**

Human 1	-----TATCAGTCGAGATTCTGAA
Human 2	----- <u>CGATAGATAGTGGAAAGTCCC GTATCAGTCGAGATTCTGAA</u>
Calf 1	<u>GATGGTACTGGATAGATAGTGGAAAGTCCC GTATCAGTCGAGATTCTGAA</u>
Calf 2	-----TATCAGTC <u>GAGATTCTGAA</u> *****
Human 1	<u>ATTAATTGGACATCAAGTTATAATGCAAGCTGGTTATTAAGATTCAAATT</u>
Human 2	<u>ATTAATTGGACATCAAGTTATAATGCAAGCTGGTTATTAAGATTCAAATT</u>
Calf 1	<u>ATTAATTGGACATCAAGTTATAAAAGCAAGCTGGTTATTAAGATTCAAATT</u>
Calf 2	<u>ATTAATTGGACATCAAGTTATAAAAGCAAGCTGGTTATTAAGATTCAAATT</u> *****
Human 1	TCCTTTGAAAAGTGTGGTTTTGATATTGGAGGGTTAGGAAGAACGC
Human 2	TCCTTTGAAAAGTGTGGTTTTGATATTGGAGGGTTAGGAAGAACGC
Calf 1	TCCCTTGAAAAGTGTGGCTTTTGATATTGGAGGGTTAGGAAGAACGC
Calf 2	TCCCTTGAAAAGTGTGGCTTTTGATATTGGAGGGTTAGGAAGAACGC ***
Human 1	CGTGTGGCTTATAGATTCTGAGCTTCTTGTGCAGTTGTGGTACAGTA
Human 2	CGTGTGGCTTATAGATTCTGAGCTTCTTGTGCAGTTGTGGTACAGTA
Calf 1	CGTGTGGCTTATAGATTCTGAGCTTCTTGTGCAGTTGTGGTACAGTA
Calf 2	CGTGTGGCTTATAGATTCTGAGCTTCTTGTGCAGTTGTGGTACAGTA *****
Human 1	GCTTATGATTCTGGTGGACTGAATCCAATAATTCAGAGCTAATTAA
Human 2	GCTTATGATTCTGGTGGACTGAATCCAATAATTCAGAGCTAATTAA
Calf 1	GCTTATGATTCTGGTGGCTGAATCCAATAATTCAGAGCTAATTAA
Calf 2	GCTTATGATTCTGGTGGCTGAATCCAATAATTCAGAGCTAATTAA *****
Human 1	GCAGACTGATGAAATTATTAGTAAAGAGCCAAAGCTTGATTTCCAGGCT
Human 2	GCAGACTGATGAAATTATTAGTAAAGAGCCAAAGCTTGATTTCCAGGCT
Calf 1	GCAGACTGATGAAATTATTAGTAAAGAGCCAAAGCTTGATTTCCAGGTT
Calf 2	GCAGACTGATGAAATTATTAGTAAAGAGCCAAAGCTTGATTTCCAGGTT *****
Human 1	ACAATAATTGAACTGTACAGATGCTGGGAGAATAATTATCAGTCGGT

Human 2	ACAATAATTGAACTGTACAGATGCTGGAGAATAATTATCAGTCGGT
Calf 1	ACAATAATTGAACTGTACAGATGCTGGAGAATAATTATCAGTTGGT
Calf 2	ACAATAATTGAACTGTACAGATGCTGGAGAATAATTATCAGTTGGT

\*\*\*\*\*

Human 1	CTTGTCAAAATGTTCAAATATCCTGGACTCAGCTGGAGCTCATATCA
Human 2	CTTGTCAAAATGTTCAAATATCCTGGACTCAGCTGGAGCTCATATCA
Calf 1	CTTGTCAAAATGTCCTCAAATATCCTGGACTCAGCTGGAGCTCGTATCA
Calf 2	CTTGTCAAAATGTCCTCAAATATCCTGGACTCAGCTGGAGCTCGTATCA

\*\*\*\*\*

Human 1	GAGTCGTTAAACTTCCTAGCATCAACTTTAATTGGAAAGAGGATTCAA
Human 2	GAGTCGTTAAACTTCCTAGCATCAACTTTAATTGGAAAGAGGATTCAA
Calf 1	GAGTCGTTAAACTTCCTAGTATCAACTTTAATTGGAAAGAGGATTCAA
Calf 2	GAGTCGTTAAACTTCCTAGTATCAACTTTAATTGGAAAGAGGATTCAA

\*\*\*\*\*

Human 1	<u>CTAACGAAGGAGGGACCAAGTTACCATAATTCTTATTGGATCTCCA</u>
Human 2	<u>CTAACGAAGGAGGGACCAAGTTACCATAATTCTTATTGGATCTCCA</u>
Calf 1	<u>CTAACGAAGGAGGGACCAAGTTACCATAATTCTTATTGGATCTCCA</u>
Calf 2	<u>CTAACGAAGGAGGGACCAAGTTACCATAATTCTTATTGGATCTCCA</u>

\*\*\*\*\*

Human 1	AGGTATAAGCAGAAGAAAACATTTATTGGGATCAGGATCCAGGTACTAT
Human 2	AGGTATAAGCAGAAGAAAACATTTATTGGGATCAGGATCCAGGTACTAT
Calf 1	AGGTATAAGCAGAAGAAAACATTTATTGGGATCAGGATCCAGGTACTAT
Calf 2	AGGTATAAGCAGAAGAAAACATTTATTGGGATCAGGATCCAGGTACTAT

\*\*\*\*\*

Human 1	TCCAGTTGCTGATGAAATGAAGCTCATGGTTAACCGCTAACCAA
Human 2	TCCAGTTGCTGATGAAATGAAGCTCATGGTTAACCGCTAACCAA
Calf 1	TCCAGTTGCTGATGAAATGAAGCTCATGGTTAACCGCTAACCAA
Calf 2	TCCAGTTGCTGATGAAATGAAGCTCATGGTTAACCGCTAACCAA

\*\*\*\*\*

Human 1	CATACCATCCTTGGCTAGAAGCTCATCTGGAA-----
Human 2	CATACCATCCTTGGCTAGAAGCTCATCTGGAAAGTTTG-----
Calf 1	CATACCATCCTTGGATAGAAGCTCATCTGGAAAGTTTGAGTCTGATAGT
Calf 2	CATACCATCCTTGGATAGAAGCTCATCTGGAAAGTTTG-----

\*\*\*\*\*

Human 1	-----
Human 2	-----
Calf 1	<u>ACAGAATCCGGCGTGC</u> AATGAAGAAAGAAACGATAAC
Calf 2	-----

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/AU 96/00387

## A. CLASSIFICATION OF SUBJECT MATTER

Int Cl<sup>6</sup>: C07H 21/04, C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
C12Q 1/68, C07H 21/04Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
AU : IPC as aboveElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
DERWENT: CRYPTOSPORIDIUM

CHEMICAL ABSTRACTS: CRYPTOSPORIDIUM and (DNA or probe# or hybridisation#)

CHEMICAL ABSTRACTS ggtactggatag; tcgcacgcccgg, gagattctgaaa, ctccttcgttag

NUCLEOTIDE SEQUENCE SEARCH:

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94/02635 A1 (The Minister of Agriculture Fisheries and Food in her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern Ireland), 3 February 1994 entire document	1-15
A	WO 94/04681 A1 (Istituto Superiore Di Sanita), 3 March 1994 entire document	1-15

Further documents are listed in the continuation of Box C

See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 July 1996

Date of mailing of the international search report

27.08.96

Name and mailing address of the ISA/AU  
AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION  
PO BOX 200  
WODEN ACT 2606  
AUSTRALIA Facsimile No.: (06) 285 3929

Authorized officer

TERRY SUMMERS

Telephone No.: (06) 283 2291

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	American Journal of Tropical Medicine and Hygiene, Volume 45, No. 6, 1991, M.A. Laxer et al, "DNA sequences for the specific detection of <i>Cryptosporidium parvum</i> by the polymerase chain reaction", pages 688-694. entire document	1-15
A	Journal of Eukaryotic Microbiology, Volume 42, No. 4, 1995 N.V. Khramtsov et al, "Cloning and analysis of a <i>Cryptosporidium parvum</i> gene encoding a protein with homology to cytoplasmic form Hsp 70", pages 416-422. entire document	1-15
A	Veterinary Parasitology, Volume 50, 1993, K.A. Webster et al, "Detection of <i>Cryptosporidium parvum</i> using a specific polymerase chain reaction", pages 35-44. entire document	1-15
P,A	Applied and Environmental Microbiology, Volume 62, No. 2, February 1996, X. Leng et al, "Simplified method for recovery and PCR detection of <i>Cryptosporidium</i> DNA from Bovine faeces", pages 643-647. entire document	1-15
A	American Journal of Tropical Medicine and Hygiene, Volume 52, No. 6, 1995 U.M. Morgan et al, "Molecular characterisation of <i>Cryptosporidium</i> isolates from human and other animals using random amplified polymorphic DNA analysis", pages 559-564. entire document	1-15

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No.  
**PCT/AU 96/00387**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO	9402635	EP	652974	GB	9215656
END OF ANNEX					

